# Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

> **NCT05033587** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 28 (estimated)

## Conditions studied

- MGMT-Unmethylated Glioblastoma

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** AK105
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05033587
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2021-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05033587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05033587, "Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05033587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*